Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomised, multicentre, double‐blind, phase 3 trial in China

Journal:

Arthritis & Rheumatology

Published:

2025-05-27

DOI:

10.1002/art.43261

Affiliations:

17

Authors:

20

Go to article

Institutions	Authors	Share
Eisai, Japan	3.000000	0.15
Peking University First Hospital, PKUHSC, China	2.000000	0.10
The First Hospital of Jilin University, China	1.000000	0.05
The First Affiliated Hospital of Dalian Medical University, China	1.000000	0.05
Foshan First People's Hospital, China	1.000000	0.05
Eisai China, China	1.000000	0.05
The Second Hospital of Dalian Medical University, China	1.000000	0.05
The Third Xiangya Hospital, CSU, China	1.000000	0.05
Zhujiang Hospital of Southern Medical University, China	1.000000	0.05
Shanghai Tongren Hospital, SJTU, China	1.000000	0.05
Shenzhen People’s Hospital, China	1.000000	0.05
Jieyang People's Hospital, China	1.000000	0.05
Dalian Central Hospital, DUT, China	1.000000	0.05
Second Affiliated Hospital of Nanjing Medical University, China	1.000000	0.05
Beijing Hospital, China	1.000000	0.05
Pingxiang People's Hospital, China	1.000000	0.05
The Affiliated Hospital of Qingdao University, China	1.000000	0.05

Interested in Clinical Sciences?